SCHEMBL13465715

SCHEMBL13465715

C=CC[C@H](NC(C)=O)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.55
KDM4E B2RXH2 1/20 0.55
THRB P10828 1/20 0.55
ALOX15 P16050 1/20 0.55
NFKB1 P19838 1/20 0.55
PTGS2 P35354 1/20 0.55
THPO P40225 1/20 0.55
RECQL P46063 1/20 0.55
BLM P54132 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
ALDH1A1 P00352 2/20 0.53
GNPAT O15228 2/20 0.41
TGFBR1 P36897 1/20 0.41
FOLH1 Q04609 3/20 0.38
GRIK1 P39086 2/20 0.37
GRIK2 Q13002 2/20 0.37
CYP2C19 P33261 1/20 0.36
CPA1 P15085 1/20 0.36
LMNA P02545 1/20 0.36
NAALAD2 Q9Y3Q0 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15497996 1.00 MAPT (0.55) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL713231 1.00 MAPT (0.55) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL1463629 0.86 MAPT (0.41) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL19003911 0.85 KDM4E (0.42) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL10074584 0.82 KDM4E (0.39) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL11732508 0.81 MAPT (0.57) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL11984630 0.81 MAPT (0.57) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL713948 0.80 KDM4E (0.38) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL627305 0.80 TGFBR1 (0.39) MAPTKDM4ETHRBALOX15NFKB1
SCHEMBL5562691 0.80 ACE (0.43) MAPTKDM4ETHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2025-11-18 US disclosed
US-12297205-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2025-05-13 US disclosed
US-20240059702-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2024-02-22 US disclosed
US-20240043470-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS UNIV CORNELL (US) 2024-02-08 US disclosed
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors CORNELL UNIVERSITY (US) 2023-12-05 US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 US disclosed
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-08-08 US disclosed
US-20220324907-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE 2022-10-13 US disclosed
EP-3589287-B1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS INC (US) 2022-09-14 EP disclosed
US-20210300934-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2021-09-30 US disclosed
US-11053253-B2 Macrocyclic compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2021-07-06 US disclosed
EP-3694508-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS Cornell University (US) 2020-08-19 EP disclosed
WO-2019075259-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS CORNELL UNIVERSITY (US) 2019-04-18 WO disclosed
WO-2018160892-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. (US) 2018-09-07 WO disclosed
WO-2012140507-A1 PRODUCTION OF ENANTIOMERICALLY PURIFIED AMINO ACIDS DR. REDDY'S LABORATORIES (EU) LIMITED (GB) 2012-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043470-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS PSMB5, PSMB1, PSMB3 MAPT 1702/4885KDM4E 729/4885THRB 3085/4885
US-11718626-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH MAPT 3729/4885KDM4E 3629/4885THRB 2795/4885
US-11053253-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH MAPT 3729/4885KDM4E 3629/4885THRB 2795/4885
US-11834515-B2 Macrocyclic compounds as proteasome inhibitors PSMB5, PSMB1, PSMB3 MAPT 1702/4885KDM4E 729/4885THRB 3085/4885
US-12473331-B2 Macrocyclic compounds as proteasome inhibitors PSMB5, PSMB1, PSMB3 MAPT 1702/4885KDM4E 729/4885THRB 3085/4885
US-20210300934-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH MAPT 3729/4885KDM4E 3629/4885THRB 2795/4885
US-12297205-B2 Macrocyclic compounds for treatment of medical disorders CFD, TFPI, CFH MAPT 3729/4885KDM4E 3629/4885THRB 2795/4885
US-20220324907-A1 MACROCYCLIC COMPOUNDS AS PROTEASOME INHIBITORS PSMB5, PSMB1, PSMB3 MAPT 1702/4885KDM4E 729/4885THRB 3085/4885
US-20240059702-A1 MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH MAPT 3729/4885KDM4E 3629/4885THRB 2795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.